- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
$25M federal funding boost for Australian Drug Discovery Centre
14 January 2019
Federal Health Minister Greg Hunt has today announced $25 million in funding to enhance Australia’s drug discovery capabilities at the Walter and Eliza Hall Institute’s new Drug Discovery Centre.
platform currently being installed in the Drug Discovery
Centre
This significant investment is helping to overcome a challenge in Australian drug discovery by enabling the translation of world-class Australian biomedical research into lifesaving medicines for patients.
The funding builds upon the Institute’s own $32.1 million investment in the Centre, as well as generous philanthropic and state government support.
Bridging a vital gap in Australian drug discovery
The Institute’s Drug Discovery Centre will offer the latest robotic equipment and expertise to researchers, so they can undertake ultra-high-throughput chemical screening. This is a critical step in the drug discovery pipeline that allows researchers to identify the exact chemical compounds needed to develop medicines that treat disease.
Institute director Professor Doug Hilton thanked the federal government for recognising the importance of a Drug Discovery Centre for the whole Australian medical research sector that fills a vital gap in our drug discovery pipeline.
“In a landmark move for Australian medical research, the Institute has established a Drug Discovery Centre so that researchers in Australia can screen and pinpoint the exact chemical compounds needed to progress their basic research discoveries into new medicines.
“For many years the translation of world-class Australian research into new medicines has been hampered by a lack of capacity for drug development. This meant that many promising research discoveries were either never pursued, or researchers were forced overseas to develop their research into new therapies,” Professor Hilton said.
Increased capacity for developing new medicines
The Institute’s head of new medicines and diagnostics Associate Professor Guillaume Lessene said the injection of federal government funding would triple the Centre’s screening capacity over the next two years.
“The additional funding means we are now able to recruit additional highly skilled scientists and open the Centre up to the Australian medical research sector from June 2019,” he said.
Executive director of Children’s Cancer Institute Michelle Haber said a nationally-accessible Drug Discovery Centre would increase the probability of developing lifesaving medicines.
“The Drug Discovery Centre is a great example of how as a nation we can excel in health and medical research on the international stage. The whole sector's accessibility to the Centre will serve to increase Australia’s capacity for drug discovery, bringing hope to patients in Australia and around the world,” she said.
Proven track-record for translation
Institute director Professor Doug Hilton with Health Minister
Greg Hunt MP in the Drug Discovery Centre
The Institute’s own contribution to the establishment of the new centre has come from philanthropic and state government support, as well as $32.1 million from the sale of royalty rights for venetoclax, an anti-cancer treatment based on a landmark research discovery made at the Institute in the 1980s.
Professor Hilton said the Institute had a proven track-record for translating its research into health outcomes for patients.
“Venetoclax is a leading example of how patients can benefit from the translation of basic research discoveries made in Australia. While that medicine took 30 years to reach patients, we hope that our commitment to building a centre that enhances Australia’s capacity for translating basic biomedical research will serve to accelerate the process of drug discovery bringing future medicines to patients faster.”
An important investment
Minister Hunt said the $25 million contribution from the Coalition Government would help the innovative centre save lives.
“Our investment in this important Drug Discovery Centre will help researchers develop news drugs to treat both common and rare diseases and improve the quality of life of many Australians,” Mr Hunt said.
“Our Government’s contribution to this significant centre is through our landmark Medical Research Future Fund (MRFF). The MRFF is an endowment fund, which will mature at $20 billion, providing a sustainable source of funding for vital medical research. It is the single largest boost in health and medical research funding in Australia’s history.”
The latest innovative technology
Thermo Scientific has been engaged to take the Institute’s small molecule screening capabilities and capacity to the next level. The Drug Discovery Centre has collaboratively designed three, highly flexible, expandable, ultra-high throughput screening platforms with Thermo Scientific that are currently being installed in the new centre.
Media enquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
The NDDC enables medical researchers to access ultra-high throughput screening, fast tracking scientific discoveries into new medicines.
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.
A landmark deal from the partial sale of royalty rights in anti-cancer treatment venetoclax secures the Institute’s place for innovation in medical research.
Starting with a landmark discovery in 1988, follow the story of how Institute research has driven development of a breakthrough anti-cancer drug.